BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 29926700)

  • 1. Molecular Minimal Residual Disease in Acute Myeloid Leukemia.
    Mauvieux L; Miguet L; Fornecker L
    N Engl J Med; 2018 Jun; 378(25):2442-3. PubMed ID: 29926700
    [No Abstract]   [Full Text] [Related]  

  • 2. How Do We Use Multicolor Flow Cytometry to Detect Minimal Residual Disease in Acute Myeloid Leukemia?
    Xu J; Jorgensen JL; Wang SA
    Clin Lab Med; 2017 Dec; 37(4):787-802. PubMed ID: 29128069
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular Minimal Residual Disease in Acute Myeloid Leukemia.
    Ulrich BC
    N Engl J Med; 2018 Jun; 378(25):2442. PubMed ID: 29926698
    [No Abstract]   [Full Text] [Related]  

  • 4. Molecular Minimal Residual Disease in Acute Myeloid Leukemia.
    Löwenberg B; Valk PJM
    N Engl J Med; 2018 Jun; 378(25):2443. PubMed ID: 29924951
    [No Abstract]   [Full Text] [Related]  

  • 5. Monitoring of minimal residual disease in acute myeloid leukemia: methods and best applications.
    Jorgensen JL; Chen SS
    Clin Lymphoma Myeloma Leuk; 2011 Jun; 11 Suppl 1():S49-53. PubMed ID: 22035748
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acute Myeloid Leukemia Immunophenotyping by Flow Cytometric Analysis.
    Chen X; Cherian S
    Clin Lab Med; 2017 Dec; 37(4):753-769. PubMed ID: 29128067
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Minimal Residual Disease in Acute Myeloid Leukemia.
    Sung PJ; Luger SM
    Curr Treat Options Oncol; 2017 Jan; 18(1):1. PubMed ID: 28110381
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patient-tailored analysis of minimal residual disease in acute myeloid leukemia using next-generation sequencing.
    Malmberg EB; StÄhlman S; Rehammar A; Samuelsson T; Alm SJ; Kristiansson E; Abrahamsson J; Garelius H; Pettersson L; Ehinger M; Palmqvist L; Fogelstrand L
    Eur J Haematol; 2017 Jan; 98(1):26-37. PubMed ID: 27197529
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Advances in minimal residual disease detection with flow cytometry in childhood acute myeloid leukemia].
    Feng JH; Xu XJ; Tang YM
    Zhonghua Er Ke Za Zhi; 2013 Mar; 51(3):231-4. PubMed ID: 23751588
    [No Abstract]   [Full Text] [Related]  

  • 10. A refined approach to detect and measure minimal residual disease in childhood acute myeloid leukemia by flow cytometry.
    Capolunghi F; Capponi C; De Stefani B; Luciani M; Locatelli F; Muraca M; Carsetti R
    Am J Hematol; 2014 Mar; 89(3):343-4. PubMed ID: 24265183
    [No Abstract]   [Full Text] [Related]  

  • 11. Stability of leukemia-associated aberrant immunophenotypes in patients with acute myeloid leukemia between diagnosis and relapse: comparison with cytomorphologic, cytogenetic, and molecular genetic findings.
    Voskova D; Schoch C; Schnittger S; Hiddemann W; Haferlach T; Kern W
    Cytometry B Clin Cytom; 2004 Nov; 62(1):25-38. PubMed ID: 15468339
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Detection of minimal residual disease in leukemia using flow cytometry].
    Muroi K
    Rinsho Ketsueki; 2008 Jun; 49(6):397-407. PubMed ID: 18646607
    [No Abstract]   [Full Text] [Related]  

  • 13. [Measurement of minimal residual disease and its implication].
    Tsurusawa M; Hori T
    Nihon Rinsho; 2012 Apr; 70 Suppl 2():731-6. PubMed ID: 23134035
    [No Abstract]   [Full Text] [Related]  

  • 14. The role of multiparameter flow cytometry for detection of minimal residual disease in acute myeloid leukemia.
    Al-Mawali A; Gillis D; Lewis I
    Am J Clin Pathol; 2009 Jan; 131(1):16-26. PubMed ID: 19095561
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Minimal residual disease detection by flow cytometry.
    Ludwig WD
    Lab Hematol; 2004; 10(3):169. PubMed ID: 15529435
    [No Abstract]   [Full Text] [Related]  

  • 16. Flow cytometry reveals the nuances of clonal haematopoiesis.
    Hasserjian RP
    Br J Haematol; 2021 Mar; 192(6):949-950. PubMed ID: 33605429
    [No Abstract]   [Full Text] [Related]  

  • 17. [Quantification of minimal residual disease by multiparameter flow cytometry in acute myeloid leukemia. From diagnosis to prognosis].
    Kern W; Haferlach T
    Med Klin (Munich); 2005 Jan; 100(1):54-9. PubMed ID: 15654545
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Readying the minimal residual disease concept in acute myeloid leukaemia for prime time - the American way.
    Hokland P; Cotter F
    Br J Haematol; 2013 Aug; 162(4):429-30. PubMed ID: 23772825
    [No Abstract]   [Full Text] [Related]  

  • 19. The Prognostic Significance of Measurable ("Minimal") Residual Disease in Acute Myeloid Leukemia.
    Buccisano F; Hourigan CS; Walter RB
    Curr Hematol Malig Rep; 2017 Dec; 12(6):547-556. PubMed ID: 29027628
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of processing time on analysis of rare event in minimal residual disease study.
    Rai S; Bhardwaj U; Singh S; Misra A
    Indian J Pathol Microbiol; 2017; 60(3):449-451. PubMed ID: 28937402
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.